When you're looking at a new investment for the first time, the best place to start is the company's last quarterly report. Take, for example, health-care stalwart and reliable dividend stock Johnson & Johnson . The company reported strong results and raised its guidance for the year; but what were the major growth drivers, and how does its valuation stack up against competitors like Abbott Labs ? In the following video, a segment from The Motley Fool's health-care show Market Checkup, analysts David Williamson and Max Macaluso examine the highs and lows of the company's second quarter.
One of the best parts of owning big pharma stocks like Johnson & Johnson is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report, "Secure Your Future With 9 Rock-Solid Dividend Stocks," outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
The article Johnson & Johnson's Earnings Made Easy originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.